Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
17 hedge funds and large institutions have $7.22M invested in Oncternal Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.
9% less capital invested
Capital invested by funds: $7.96M → $7.22M (-$742K)
19% less funds holding
Funds holding: 21 → 17 (-4)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$819K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$54.2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.4K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.47K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$733 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FHA
First Horizon Advisors
Memphis,
Tennessee
|
-$601K |
| 2 |
Millennium Management
New York
|
-$142K |
| 3 |
KLI
Kelman-Lazarov Inc
Memphis,
Tennessee
|
-$8.13K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$5.86K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$2.93K |
ONCT Hedge Fund Activity: Q1 2017 in Review
17 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2017, worth a combined $7.22M — down 9.3% from $7.96M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ONCT and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.
The largest buyer was BlackRock, opening a new position worth an estimated $819K. The largest seller was First Horizon Advisors, cutting an estimated $601K.
- 17 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2017, down from 21 in Q4 2016.
- Funds reported $7.22M of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2017, down 9.3% quarter-over-quarter.
- 3 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2017 and 4 closed out, a net change of -1 holder.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $819K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2017 was First Horizon Advisors, an estimated $601K sold.
Based on aggregated 13F filings for Q1 2017.